Clinical Trials Browser

INDUSTRY × Hematologic Neoplasms × durvalumab × Clear all

NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

Phase 1/2 Active not recruiting

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms